Congruence

Artificial Intelligence · Biotechnology
Lately:1 news story in 90 daysFollow changes →

Facts

as of Nov 17, 2026

We are a drug discovery company that is uniquely harnessing the power of protein dynamics, biophysics, machine learning and computational chemistry.

Employees
11-50estimated range
Official records
Wikidata Q140046090
Website
congruencetx.com

These are the key facts about Congruence on Alion as of Nov 17, 2026. The latest round is Venture - Series Unknown of $39.5M, announced in 2026.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Financials

Funding rounds, investors and revenue on record.

$39.5MTotal raised
Venture - Series UnknownLatest round
1Rounds and grants
Money by yearUSD, rounds and grants
2026$39.5M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers

Milestones

Mar 19
Raised a round Venture round $39.5M
Nov 2021
Each milestone is dated by its source: registers, filings, the press

Newsroom

Oct 32026
News · noteノート
Up until the last post, I talked about the client's self-congruence, where the client aligns their own ideals with their reality. This time, I would like to think about the secon…
Apr 202026
Press release
https://www.prnewswire.com/news-releases/congruence-announces-participation-at-the-2026-bloom-burton-co-healthcare-investor-conference-302747214.html The post Congruence Announce…
Apr 92026
Press release
https://www.prnewswire.com/news-releases/congruence-announces-participation-in-the-25th-annual-needham-virtual-healthcare-conference-302738712.html?tc=eml_cleartime The post Cong…
Mar 192026
Press release
https://www.prnewswire.com/news-releases/congruence-announces-39-5m-financing-to-advance-portfolio-of-small-molecule-correctors-into-the-clinic-302718764.html?tc=eml_cleartime Th…
Mar 192026
Blog
Essai clinique de phase 1/1b en cours avec le CGX-926 pour l'obésité génétique liée à un déficit en MC4R Programmes sur la maladie de Parkinson et le déficit en alpha-1-antitryps…
Mar 192026
Press release
https://www.prnewswire.com/news-releases/congruence-announces-first-dosing-in-phase-11b-clinical-trial-of-cgx-926-a-first-in-class-oral-mc4r-corrector-for-genetic-obesity-3027187…
Sources: the outlets named on each headline, each story once